Results 1 - 20 of 3,912 for All Library Resources
Sorted by:
Sorted by:
RelevanceOr hit Enter to replace sort method
- Relevance
- Date-newest
- Date-oldest
- Popularity
- Author
- Title
Show only
- Peer-reviewed Journals (3,590)
| Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
|---|---|---|---|
| 1 |
Material Type: Article
|
|
Asciminib for CML: same target, new arrowBlood, 2021-11, Vol.138 (21), p.2009-2010 [Peer Reviewed Journal]2021 American Society of Hematology ;ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood.2021013257 ;PMID: 34821938Full text available |
| 2 |
Material Type: Article
|
|
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trialThe lancet oncology, 2017-12, Vol.18 (12), p.1624-1636 [Peer Reviewed Journal]2017 Elsevier Ltd ;Copyright © 2017 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Dec 1, 2017 ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(17)30683-6 ;PMID: 29107679Full text available |
| 3 |
Material Type: Article
|
|
Nicotinamide Riboside Preserves Cardiac Function in a Mouse Model of Dilated CardiomyopathyCirculation (New York, N.Y.), 2018-05, Vol.137 (21), p.2256-2273 [Peer Reviewed Journal]2018 by the American College of Cardiology Foundation and the American Heart Association, Inc. ;2017 American Heart Association, Inc. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.116.026099 ;PMID: 29217642Full text available |
| 4 |
Material Type: Article
|
|
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trialThe Lancet (British edition), 2018-03, Vol.391 (10126), p.1163-1173 [Peer Reviewed Journal]2018 Elsevier Ltd ;Copyright © 2018 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Mar 24, 2018 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(18)30207-1 ;PMID: 29433850Full text available |
| 5 |
Material Type: Article
|
|
NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NRCell metabolism, 2018-03, Vol.27 (3), p.513-528 [Peer Reviewed Journal]2017 Elsevier Inc. ;Copyright © 2017 Elsevier Inc. All rights reserved. ;ISSN: 1550-4131 ;EISSN: 1932-7420 ;DOI: 10.1016/j.cmet.2017.11.002 ;PMID: 29249689Full text available |
| 6 |
Material Type: Article
|
|
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet (British edition), 2017-01, Vol.389 (10064), p.56-66 [Peer Reviewed Journal]Elsevier Ltd ;2017 Elsevier Ltd ;Copyright © 2017 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jan 7, 2017 ;2017. Elsevier Ltd ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(16)32453-9 ;PMID: 27932229 ;CODEN: LANCAOFull text available |
| 7 |
Material Type: Article
|
|
The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s diseaseCell metabolism, 2022-03, Vol.34 (3), p.396-407.e6 [Peer Reviewed Journal]2022 The Authors ;Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved. ;ISSN: 1550-4131 ;EISSN: 1932-7420 ;DOI: 10.1016/j.cmet.2022.02.001 ;PMID: 35235774Full text available |
| 8 |
Material Type: Article
|
|
NAD + supplementation reduces neuroinflammation and cell senescence in a transgenic mouse model of Alzheimer's disease via cGAS-STINGProceedings of the National Academy of Sciences - PNAS, 2021-09, Vol.118 (37) [Peer Reviewed Journal]Copyright National Academy of Sciences Sep 14, 2021 ;2021 ;ISSN: 0027-8424 ;EISSN: 1091-6490 ;DOI: 10.1073/pnas.2011226118 ;PMID: 34497121Full text available |
| 9 |
Material Type: Article
|
|
CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent MechanismCell metabolism, 2016-06, Vol.23 (6), p.1127-1139 [Peer Reviewed Journal]2016 Elsevier Inc. ;Copyright © 2016 Elsevier Inc. All rights reserved. ;ISSN: 1550-4131 ;EISSN: 1932-7420 ;DOI: 10.1016/j.cmet.2016.05.006 ;PMID: 27304511Full text available |
| 10 |
Material Type: Article
|
|
Nicotinamide riboside is uniquely and orally bioavailable in mice and humansNature communications, 2016-10, Vol.7 (1), p.12948-14, Article 12948 [Peer Reviewed Journal]Copyright Nature Publishing Group Oct 2016 ;Copyright © 2016, The Author(s) 2016 The Author(s) ;ISSN: 2041-1723 ;EISSN: 2041-1723 ;DOI: 10.1038/ncomms12948 ;PMID: 27721479Full text available |
| 11 |
Material Type: Article
|
|
NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cellsNature communications, 2016-10, Vol.7 (1), p.13103-13103, Article 13103 [Peer Reviewed Journal]Copyright Nature Publishing Group Oct 2016 ;Copyright © 2016, The Author(s) 2016 The Author(s) ;ISSN: 2041-1723 ;EISSN: 2041-1723 ;DOI: 10.1038/ncomms13103 ;PMID: 27725675Full text available |
| 12 |
Material Type: Article
|
|
Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD + in healthy middle-aged and older adultsNature communications, 2018-03, Vol.9 (1), p.1286-11, Article 1286 [Peer Reviewed Journal]2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2018 ;ISSN: 2041-1723 ;EISSN: 2041-1723 ;DOI: 10.1038/s41467-018-03421-7 ;PMID: 29599478Full text available |
| 13 |
Material Type: Article
|
|
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIsBlood, 2021-11, Vol.138 (21), p.2031-2041 [Peer Reviewed Journal]2021 American Society of Hematology ;2021 by The American Society of Hematology. ;ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood.2020009984 ;PMID: 34407542Full text available |
| 14 |
Material Type: Article
|
|
New knowledge of the mechanisms of sorafenib resistance in liver cancerActa pharmacologica Sinica, 2017-05, Vol.38 (5), p.614-622 [Peer Reviewed Journal]Copyright Nature Publishing Group May 2017 ;Copyright © 2017 CPS and SIMM 2017 CPS and SIMM ;ISSN: 1671-4083 ;EISSN: 1745-7254 ;DOI: 10.1038/aps.2017.5 ;PMID: 28344323Full text available |
| 15 |
Material Type: Article
|
|
Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory SignaturesCell reports (Cambridge), 2019-08, Vol.28 (7), p.1717-1728.e6 [Peer Reviewed Journal]2019 The Author(s) ;Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved. ;2019 The Author(s) 2019 ;ISSN: 2211-1247 ;EISSN: 2211-1247 ;DOI: 10.1016/j.celrep.2019.07.043 ;PMID: 31412242Full text available |
| 16 |
Material Type: Article
|
|
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trialThe Lancet (British edition), 2016-05, Vol.387 (10032), p.2008-2016 [Peer Reviewed Journal]Elsevier Ltd ;2016 Elsevier Ltd ;Copyright © 2016 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited May 14, 2016 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(16)00559-6 ;PMID: 26969090 ;CODEN: LANCAOFull text available |
| 17 |
Material Type: Article
|
|
NAD+ supplementation normalizes key Alzheimer’s features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiencyProceedings of the National Academy of Sciences - PNAS, 2018-02, Vol.115 (8), p.E1876-E1885 [Peer Reviewed Journal]Volumes 1–89 and 106–114, copyright as a collective work only; author(s) retains copyright to individual articles ;Copyright National Academy of Sciences Feb 20, 2018 ;2018 ;ISSN: 0027-8424 ;EISSN: 1091-6490 ;DOI: 10.1073/pnas.1718819115 ;PMID: 29432159Full text available |
| 18 |
Material Type: Article
|
|
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trialThe Lancet (British edition), 2014-07, Vol.384 (9940), p.319-328 [Peer Reviewed Journal]Elsevier Ltd ;2014 Elsevier Ltd ;2015 INIST-CNRS ;Copyright © 2014 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jul 26, 2014 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(14)60421-9 ;PMID: 24768112 ;CODEN: LANCAOFull text available |
| 19 |
Material Type: Article
|
|
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trialThe lancet oncology, 2015-07, Vol.16 (7), p.859-870 [Peer Reviewed Journal]Elsevier Ltd ;2015 Elsevier Ltd ;Copyright © 2015 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jul 2015 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(15)00050-9 ;PMID: 26095784 ;CODEN: LANCAOFull text available |
| 20 |
Material Type: Article
|
|
SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinomaJournal of clinical oncology, 2015-02, Vol.33 (6), p.559-566 [Peer Reviewed Journal]2014 by American Society of Clinical Oncology. ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2013.53.7746 ;PMID: 25547503Full text available |
Results 1 - 20 of 3,912 for All Library Resources
Sorted by:
Sorted by:
RelevanceOr hit Enter to replace sort method
- Relevance
- Date-newest
- Date-oldest
- Popularity
- Author
- Title
Personalize your results
Refine Search Results
Expand My Results
Show only
- Peer-reviewed Journals (3,590)
Refine My Results
Creation Date
- Before 1980 (107)
- 1980 To 1989 (251)
- 1990 To 1999 (346)
- 2000 To 2010 (795)
- After 2010 (2,414)
-
More options
New Records
Resource Type
- Articles (3,910)
- Conference Proceedings (1)
- magazinearticle (1)
-
More options
Subject
- Science & Technology (3,425)
- Life Sciences & Biomedicine (3,240)
- Humans (2,968)
- Male (1,894)
- Female (1,532)
- Oncology (1,508)
- Animals (1,386)
- Sorafenib (1,350)
- Middle Aged (1,119)
- Phenylurea Compounds (1,088)
- Niacinamide - Pharmacology (1,063)
- Aged (955)
- Antineoplastic Agents - Therapeutic Use (931)
- Biological And Medical Sciences (893)
- Niacinamide - Therapeutic Use (807)
- Medical Sciences (782)
- Adult (753)
- Liver Neoplasms - Drug Therapy (728)
- Carcinoma, Hepatocellular - Drug Therapy (717)
-
More options
Databases
- MEDLINE (3,912)
- Geneva Foundation Free Medical Journals at publisher websites (1,756)
- ProQuest Central (1,703)
- PubMed Central (1,120)
- DOAJ Directory of Open Access Journals (791)
- HighWire Press (Free Journals) (697)
- ROAD: Directory of Open Access Scholarly Resources (670)
- Wiley Online Library Open Access (245)
- Springer Nature OA Free Journals (227)
- Freely Accessible Journals at publisher websites (160)
- Nature Free (159)
- Public Library of Science (PLoS) Journals Open Access (108)
- IngentaConnect (75)
- ProQuest One Psychology (74)
- Oxford Journals Open Access Collection (71)
- Freely Accessible Japanese Titles (ERDB Project) (70)
- Taylor & Francis Online (60)
- Journals@Ovid Open Access Journal Collection Rolling (41)
- Cell Press Archives (30)
- Hyper Article en Ligne (HAL) (Open Access) (28)
-
More options
Language
Journal Title
- Annals Of Oncology (66)
- Bmc Cancer (54)
- British Journal Of Cancer (52)
- Clinical Cancer Research (109)
- Investigational New Drugs (52)
- Journal Of Clinical Oncology (100)
- Oncology (50)
- Oncotarget (97)
- Plos One (105)
- The Oncologist (56)
-
More options
|
||||
 |
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY |  |
(84-028) 37 755 057 | Feedback |
| 19 Nguyen Huu Tho St. Dist.7, HCM |  |
thuvien@tdtu.edu.vn | ||